Date of publication 04/12/2023, date of current version 04/12/2023.

JournalGate manuscript Identifier 10.08-2/JournalGate.2023.PUB

MOLECULAR AND CELLULAR MECHANISMS GOVERNING AXONAL DEGENERATION AND SYNAPTIC PLASTICITY IN THE CONTEXT OF NEUROPATHIC PAIN AND NEURONAL INJURY

SIDI MOHAMED [1] FATIMATA SARR[2]

[1]Department of Biochemistry, Université de Nouadhibou, 56 Rue de la Corniche, Nouadhibou, 83022, Mauritania.
[2]Department of Biochemistry, Université de Rosso, 32 Rue de l'Hopital, Rosso, Trarza 71015, Mauritania.

ABSTRACT Axonal degeneration and synaptic plasticity are critical processes underlying the pathophysiology of neuropathic pain and neuronal injury. Axonal degeneration involves a cascade of molecular events leading to the disintegration of axons following injury, contributing to the loss of neuronal connectivity and chronic pain. Concurrently, synaptic plasticity, including both structural and functional changes in synapses, plays a pivotal role in altering pain pathways, thereby facilitating the transition from acute to chronic pain states. These processes are regulated by complex interactions among signaling pathways, including Wallerian degeneration, calcium influx, activation of calpains, and mitochondrial dysfunction. Additionally, molecular pathways such as the ubiquitin-proteasome system (UPS), axonal transport mechanisms, and neurotrophic factors like brain-derived neurotrophic factor (BDNF) are key regulators of axonal integrity and synaptic modifications. In the context of neuropathic pain, maladaptive synaptic plasticity at the level of the dorsal horn and supraspinal structures leads to central sensitization, contributing to heightened pain sensitivity and persistent pain states. This review explores the molecular and cellular mechanisms governing axonal degeneration and synaptic plasticity, emphasizing their roles in the onset and maintenance of neuropathic pain. Understanding these mechanisms offers insights into potential therapeutic strategies aimed at preventing axonal degeneration, modulating synaptic changes, and ultimately improving outcomes for individuals suffering from neuropathic pain and neuronal injury. By targeting specific molecular pathways, it may be possible to attenuate chronic pain and enhance neuronal resilience, offering new avenues for the treatment of neuropathic conditions.

INDEX TERMS axonal degeneration, BDNF, central sensitization, mitochondrial dysfunction, neuropathic pain, synaptic plasticity, ubiquitin-proteasome system

I. INTRODUCTION

Neuropathic pain is a debilitating condition that arises as a result of direct injury or disease affecting the somatosensory nervous system. This type of pain is distinct from nociceptive pain in that it is not merely a response to tissue injury but results from damage to the nervous system itself, leading to altered pain processing. It is characterized by spontaneous pain, hyperalgesia, and allodynia, which persist long after the initial injury, significantly impairing quality of life and presenting a challenge to effective clinical management. Spontaneous pain refers to pain that arises without any obvious external trigger, while hyperalgesia represents an exaggerated pain response to normally painful stimuli, and allodynia is pain evoked by stimuli that are not typically painful. These clinical symptoms reflect the underlying alterations in the nervous system that sustain the abnormal pain perception. The prevalence of neuropathic pain varies depending on the underlying cause, but it is estimated to affect between 7

The pathogenesis of neuropathic pain involves complex interactions between peripheral and central nervous system components, leading to structural and functional alterations that maintain pain perception. Peripheral sensitization occurs due to increased excitability of primary sensory neurons, often resulting from upregulation of ion channels and changes in receptor expression. This increased excitability is transmitted centrally, where spinal cord neurons and other central pain-processing circuits undergo maladaptive changes, contributing to central sensitization. Central sensitization is

a state of increased responsiveness of nociceptive neurons in the central nervous system, amplifying pain signals and prolonging the sensation of pain even after the resolution of the initial injury. Two fundamental processes that play critical roles in this pathophysiological landscape are axonal degeneration and synaptic plasticity. Axonal degeneration, triggered by physical trauma, metabolic disturbances, or inflammation, results in the breakdown of axonal structures and the disruption of neural communication. This process is often characterized by Wallerian degeneration, where axons distal to the site of injury degenerate following a pattern that involves cytoskeletal breakdown and myelin clearance. This degeneration disrupts the transmission of sensory information and contributes to aberrant signaling that can manifest as chronic pain.

Synaptic plasticity, on the other hand, encompasses the ability of synapses to strengthen or weaken over time in response to changes in activity and is a key mechanism underlying learning and memory. In the context of neuropathic pain, however, these synaptic changes become maladaptive, contributing to the sensitization of pain pathways. Enhanced synaptic transmission in pain-related circuits can facilitate the perpetuation of pain signals, even in the absence of ongoing peripheral input. This phenomenon is mediated through mechanisms such as long-term potentiation (LTP) at synapses between primary afferent fibers and spinal dorsal horn neurons. LTP is a well-documented form of synaptic plasticity that involves an increase in synaptic strength, which in the context of pain, can result in exaggerated responses to sensory inputs, thereby reinforcing the chronic pain state.

The processes of axonal degeneration and synaptic plasticity are regulated by a variety of molecular pathways, including those involving calcium signaling, mitochondrial dynamics, and the activation of proteolytic enzymes like calpains. Calcium influx, through voltage-gated calcium channels or through receptors such as the N-methyl-D-aspartate (NMDA) receptor, plays a critical role in initiating both axonal degeneration and synaptic plasticity. Excessive calcium entry can lead to the activation of calpains and other proteases that degrade cytoskeletal components, contributing to axonal fragmentation. Similarly, calcium signaling is central to the induction of synaptic plasticity, where it triggers intracellular cascades that can strengthen or weaken synaptic connections. Mitochondrial function is equally important, as mitochondria serve as regulators of calcium homeostasis and energy supply, both of which are crucial for the maintenance of axonal and synaptic integrity. Mitochondrial dysfunction has been implicated in the progression of neurodegenerative processes, including those that underlie chronic pain conditions.

Another critical aspect in the context of neuropathic pain is the transport of molecules along axons, regulated by microtubule dynamics and motor proteins, such as kinesins and dyneins, which are essential for maintaining axonal integrity and supporting synaptic function. Microtubule-associated transport ensures the delivery of key structural and signaling components, such as neurotrophins and synaptic vesicles, to distal regions of the axon. Disruptions in these transport mechanisms, caused by injuries or metabolic imbalances, are closely associated with axonal degeneration and subsequent synaptic dysfunction. These disruptions can lead to a failure in maintaining the structural components of the axon and synapse, exacerbating the degenerative processes that contribute to neuropathic pain.

In this review, we explore the molecular and cellular mechanisms that govern axonal degeneration and synaptic plasticity in the context of neuropathic pain and neuronal injury. We focus on how these processes contribute to the development and persistence of pain and highlight potential therapeutic targets aimed at preventing axonal loss and maladaptive synaptic changes. Notably, recent advancements in understanding the molecular underpinnings of these processes have opened up new avenues for therapeutic intervention, such as targeting specific ion channels, modulating mitochondrial function, or using neuroprotective agents to prevent axonal breakdown. Additionally, strategies aimed at modulating synaptic plasticity, including the use of NMDA receptor antagonists and neurotrophic factors, hold promise for reducing the maladaptive synaptic changes that sustain chronic pain states.

By understanding these underlying mechanisms, we aim to provide a comprehensive overview of the potential strategies for mitigating the impact of neuropathic pain. The identification of these pathways and their respective roles in the pathogenesis of neuropathic pain emphasizes the importance of a multifaceted approach in the development of new therapies. This review seeks to integrate the latest findings in axonal degeneration and synaptic plasticity research, offering insights into how targeted interventions can reshape the landscape of neuropathic pain management.

II. MOLECULAR MECHANISMS OF AXONAL DEGENERATION

The degeneration of axons following neuronal injury is a critical component of the pathogenesis of neuropathic pain. Understanding the molecular mechanisms underlying axonal degeneration can provide insight into potential therapeutic strategies aimed at preserving neuronal integrity and mitigating chronic pain. Two principal processes involved in axonal degeneration are Wallerian degeneration and axonal autophagy, alongside disruptions in calcium signaling and mitochondrial dysfunction. These processes interact with one another, forming a complex network that ultimately determines the fate of injured axons.

A. WALLERIAN DEGENERATION AND AXONAL AUTOPHAGY

Wallerian degeneration is a well-characterized form of axonal degeneration that occurs distal to the site of injury. Unlike apoptosis, which is a form of programmed cell death affecting entire cells, Wallerian degeneration specifically affects axons, leading to their disintegration while leaving the cell body initially intact. It is triggered by the disruption

TABLE 1. Key Molecular Pathways Involved in Axonal Degeneration and Synaptic Plasticity

Molecular Pathway	Role in Neuropathic Pain	Mechanism of Action
Calcium Signaling	Initiates axonal degeneration and synaptic changes	Calcium influx activates calpains, leading to cytoskeletal degradation; in synaptic plasticity, calcium triggers signaling pathways that modify synaptic strength
Mitochondrial Dynamics	Regulates axonal and synaptic integrity	Mitochondria control calcium homeostasis and energy production; dysfunction contributes to axonal damage and synaptic failure
Proteolytic Enzymes (e.g., Calpains)	Mediates structural breakdown during axonal degeneration	Activated by calcium, calpains degrade cytoskeletal proteins and promote axonal fragmentation
Microtubule Transport	Maintains axonal integrity and synaptic function	Facilitates delivery of essential molecules along the axon; disruption can lead to axonal degeneration and synaptic loss

TABLE 2. Therapeutic Strategies Targeting Axonal Degeneration and Synaptic Plasticity

Therapeutic Strategy	Targeted Mechanism	Potential Benefits in Neuropathic Pain
Ion Channel Modulators	Target voltage-gated sodium and calcium channels	Reduce neuronal hyperexcitability and prevent excessive calcium influx associated with axonal degeneration
Mitochondrial Protectants	Enhance mitochondrial function and reduce oxidative stress	Support energy production and calcium buffering, preventing axonal damage and promoting synaptic stability
NMDA Receptor Antagonists	Block NMDA receptor-mediated calcium influx	Attenuate central sensitization and maladaptive synaptic plasticity in pain pathways
Neurotrophic Factors	Promote survival and function of neurons	Support axonal regeneration and synaptic maintenance, counteracting degeneration

of axonal transport and the subsequent breakdown of the axonal cytoskeleton, including neurofilaments and microtubules. This process is characterized by a series of cellular and molecular events that result in the rapid disassembly of axonal structures and the clearance of debris by surrounding glial cells, such as Schwann cells in the peripheral nervous system.

The axonal degeneration pathway involves the activation of SARM1 (Sterile Alpha and TIR Motif Containing 1), which plays a pivotal role in the regulation of axonal self-destruction. Upon axonal injury, SARM1 activation leads to the depletion of nicotinamide adenine dinucleotide (NAD^+), a critical coenzyme in cellular metabolism, thereby initiating a cascade of metabolic failures that contribute to axonal disintegration. The loss of NAD^+ disrupts ATP synthesis and energy metabolism within the axon, exacerbating cytoskeletal instability and promoting degeneration. The SARM1 pathway is critical for the initiation of Wallerian degeneration, and its inhibition has been shown to delay axonal breakdown, making it a promising target for therapeutic intervention to preserve axonal integrity after injury. In animal models, SARM1 inhibitors have been demonstrated to prevent axonal loss and improve outcomes following nerve injury, highlighting their potential for clinical application.

Autophagy, a cellular degradation process involving the lysosomal recycling of damaged cellular components, also plays a role in axonal degeneration. Following injury, autophagic processes can be upregulated in axons, contributing to the clearance of damaged organelles and proteins, which can help in the maintenance of axonal health. However, dysregulated autophagy can exacerbate axonal degeneration by promoting the degradation of essential structural proteins, such as microtubules and neurofilaments, which are crucial for maintaining axonal integrity. This suggests that while autophagy has a protective role in the early stages of response to injury, excessive or misregulated autophagy may contribute to the progression of axonal degeneration. The interplay between autophagy and axonal survival is thus complex, with both protective and detrimental effects depending on the context and extent of injury.

B. CALCIUM SIGNALING AND MITOCHONDRIAL DYSFUNCTION

Calcium influx is a critical mediator of axonal degeneration, especially following injury. Elevated intracellular calcium levels activate calpains, a family of calcium-dependent proteases that degrade cytoskeletal proteins like neurofilaments and microtubules, leading to axonal fragmentation. The activation of calpains disrupts the axonal cytoskeleton, causing the loss of axonal stability and continuity. This proteolytic activity not only contributes to the physical breakdown of the axon but also triggers further intracellular cascades that promote degeneration. Calcium-induced activation of calpains is thus a key event in the progression of axonal damage and represents a potential target for therapeutic strategies aimed at preventing axonal loss.

Additionally, calcium dysregulation can induce mitochondrial dysfunction, resulting in increased production of reactive oxygen species (ROS) and further damage to axonal structures. Mitochondrial health is essential for axonal maintenance, as mitochondria provide adenosine triphosphate (ATP), which is required for axonal transport, ion homeostasis, and other energy-dependent processes critical for neuronal function. When mitochondrial calcium buffering capacity is exceeded due to excessive calcium influx, it can lead to the opening of the mitochondrial permeability transition pore (mPTP), a process that results in a loss of mitochondrial membrane potential, impaired ATP synthesis,

TABLE 3. Key Processes in Axonal Degeneration and Their Molecular Mediators

Process	Molecular Mediators	Mechanism and Role in Degeneration
Wallerian Degeneration	SARM1, NAD^+ depletion	Activation of SARM1 leads to NAD^+ depletion, energy failure, and cytoskeletal breakdown, resulting in axonal disintegration
Axonal Autophagy	Autophagy-related genes (ATG), LC3, Beclin-1	Regulates the clearance of damaged cellular components; dysregulated autophagy can contribute to degradation of essential axonal structures
Cytoskeletal Breakdown	Calpains, microtubule-associated proteins	Calpain activation degrades structural proteins, leading to the collapse of axonal architecture
Mitochondrial Dysfunction	Reactive Oxygen Species (ROS), ATP synthesis disruption	Mitochondrial damage results in impaired ATP production and increased oxidative stress, promoting further axonal damage

and the release of pro-apoptotic factors. This cascade accelerates axonal degeneration by depriving the axon of necessary energy resources and increasing oxidative damage.

Mitochondrial dysfunction not only contributes to axonal degeneration but also impacts synaptic function by reducing ATP availability and increasing oxidative stress. Impaired mitochondrial transport along axons can lead to localized energy deficits at synaptic sites, thereby disrupting synaptic vesicle release and reuptake mechanisms. This can lead to impaired synaptic transmission and exacerbate the progression of neuropathic pain by altering the balance between excitatory and inhibitory neurotransmission. The role of mitochondria in oxidative stress is particularly significant, as ROS generated during mitochondrial dysfunction can damage lipids, proteins, and nucleic acids within the axon, further contributing to the degenerative process.

Targeting mitochondrial function, either by stabilizing calcium homeostasis or by using antioxidants, has been proposed as a strategy to prevent axonal and synaptic damage in neuropathic conditions. Agents that inhibit the opening of the mPTP or that enhance mitochondrial ATP production could potentially mitigate the energy deficits that drive axonal degeneration. Additionally, the use of antioxidants to neutralize ROS may help to protect axonal membranes and cytoskeletal elements from oxidative damage, thereby preserving axonal function. As such, therapies targeting calcium signaling and mitochondrial health hold promise for reducing the burden of neuropathic pain by addressing one of its key underlying mechanisms.

III. SYNAPTIC PLASTICITY IN THE CONTEXT OF NEUROPATHIC PAIN

Synaptic plasticity refers to the ability of synapses to change their strength in response to increases or decreases in activity. In the context of neuropathic pain, synaptic plasticity plays a critical role in the alteration of pain pathways, leading to a state of heightened sensitivity and persistent pain. Two major processes—central sensitization and the role of neurotrophic factors like brain-derived neurotrophic factor (BDNF)—are central to understanding how synaptic changes contribute to chronic pain states following nerve injury.

A. CENTRAL SENSITIZATION AND LONG-TERM POTENTIATION (LTP)

Central sensitization is a process where neurons within the central nervous system, particularly in the spinal dorsal horn, become more responsive to peripheral nociceptive inputs. This increased sensitivity results in pain amplification, where even mild stimuli can provoke a heightened pain response, a condition known as allodynia. Central sensitization is characterized by increased synaptic strength at pain-processing synapses, a phenomenon similar to long-term potentiation (LTP) observed in the context of learning and memory. LTP in the pain pathways occurs at glutamatergic synapses, primarily within the spinal dorsal horn, where it serves to reinforce and amplify nociceptive signals.

The molecular basis of LTP in pain pathways involves a series of events that enhance synaptic efficacy. Following nerve injury, there is an increase in the release of glutamate from primary afferent fibers. This glutamate binds to postsynaptic N-methyl-D-aspartate (NMDA) receptors, leading to the removal of the Mg^{2+} block and subsequent influx of calcium ions into the postsynaptic neuron. The increased intracellular calcium levels activate several downstream signaling pathways, including calcium/calmodulin-dependent protein kinase II (CaMKII). CaMKII plays a pivotal role in the phosphorylation of AMPA receptors and the recruitment of these receptors to the postsynaptic membrane, thereby enhancing excitatory postsynaptic potentials (EPSPs). This process results in a sustained increase in synaptic strength and contributes to the heightened perception of pain.

The activation of NMDA receptors and subsequent calcium influx also leads to the production of other signaling molecules, such as nitric oxide (NO), which can diffuse back to presynaptic terminals and facilitate further glutamate release, thus establishing a positive feedback loop that reinforces the LTP state. This feedback mechanism further contributes to the persistence of neuropathic pain by maintaining the excitatory state of spinal and supraspinal pain-processing circuits even after the initial peripheral injury has resolved. The sustained activation of these pathways results in maladaptive synaptic changes, which are a hallmark of chronic pain conditions.

TABLE 4. Effects of Calcium Dysregulation and Mitochondrial Dysfunction on Axonal Integrity

Mechanism	Impact on Axonal Integrity	Potential Therapeutic Approaches
Calcium-Induced Calpain Activation	Degradation of cytoskeletal proteins, axonal fragmentation	Calpain inhibitors to prevent breakdown of neurofilaments and microtubules
Mitochondrial Permeability Transition Pore (mPTP) Opening	Loss of ATP production, release of pro-apoptotic factors	Agents that stabilize mitochondrial membrane potential and prevent mPTP opening
Reactive Oxygen Species (ROS) Production	Oxidative damage to axonal structures, lipid peroxidation	Antioxidants to reduce ROS levels and protect axonal membranes
Impaired Mitochondrial Transport	Localized energy deficits at synaptic sites	Enhancing mitochondrial transport along axons to support synaptic function and integrity

TABLE 5. Molecular Mechanisms Underlying LTP in Pain Pathways

Molecular Component	Role in LTP and Central Sensitization	Mechanism of Action
NMDA Receptors	Facilitate calcium influx in response to glutamate	Activation leads to removal of Mg^{2+} block, allowing Ca^{2+} entry and activation of signaling pathways like CaMKII
Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII)	Enhances synaptic strength	Phosphorylates AMPA receptors and promotes their insertion into the synaptic membrane, increasing EPSPs
AMPA Receptors	Mediate fast excitatory transmission	Recruitment to the postsynaptic membrane increases synaptic response to glutamate, sustaining LTP
Nitric Oxide (NO)	Retrograde signaling molecule	Promotes presynaptic glutamate release, reinforcing synaptic potentiation through a feedback loop

B. ROLE OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IN SYNAPTIC MODULATION

BDNF is a neurotrophin that plays a pivotal role in synaptic plasticity by promoting synaptic growth, strengthening, and adaptation in both physiological and pathological conditions. In the context of neuropathic pain, BDNF serves as a critical modulator of synaptic plasticity, contributing to the mechanisms that underlie central sensitization and the transition from acute to chronic pain. After nerve injury, BDNF is released by activated microglia and sensory neurons within the spinal cord and brain, where it influences synaptic function through its action on the TrkB receptor, a high-affinity receptor for BDNF.

The interaction between BDNF and TrkB receptors initiates a cascade of intracellular signaling pathways, including the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and the mitogen-activated protein kinase (MAPK) pathway. These pathways are involved in regulating gene expression, protein synthesis, and the modulation of synaptic receptors, all of which contribute to enhanced synaptic strength. Specifically, BDNF facilitates the phosphorylation of NMDA receptors, increasing their activity and thereby amplifying calcium signaling within postsynaptic neurons. This potentiation of NMDA receptor function enhances LTP-like changes in spinal dorsal horn neurons, maintaining a state of increased excitability that underlies chronic pain perception.

Moreover, BDNF also promotes the trafficking of AMPA receptors to the synaptic membrane, further strengthening excitatory synaptic transmission. This enhanced synaptic drive plays a crucial role in maintaining central sensitization, as it allows pain-processing neurons to remain in a heightened state of responsiveness. The role of BDNF in enhancing synaptic plasticity and maintaining central sensitization makes it a key mediator of the pathological transition from acute pain, which serves as a warning signal, to chronic pain, which persists despite the absence of harmful stimuli.

The therapeutic potential of targeting BDNF-TrkB interactions has been explored in various animal models of neuropathic pain. Studies have shown that inhibition of BDNF signaling can reduce pain behaviors, decrease spinal cord hyperexcitability, and prevent the development of chronic pain following nerve injury. For example, the use of TrkB receptor antagonists has been demonstrated to block the pronociceptive effects of BDNF, reducing hyperalgesia and allodynia. This evidence suggests that modulating BDNF-TrkB signaling could represent a viable therapeutic strategy for mitigating the effects of central sensitization and alleviating chronic pain states.

The interplay between BDNF-mediated signaling and synaptic plasticity underscores the complexity of central sensitization and its role in neuropathic pain. Targeting the molecular pathways that facilitate LTP and the maladaptive synaptic changes driven by neurotrophins like BDNF could offer new therapeutic avenues for addressing chronic pain. This approach aims to break the cycle of sensitization and reduce the long-term consequences of nerve injury, ultimately improving outcomes for patients suffering from neuropathic pain.

IV. THERAPEUTIC APPROACHES TARGETING AXONAL DEGENERATION AND SYNAPTIC PLASTICITY

The treatment of neuropathic pain remains challenging due to the complexity of its underlying mechanisms, which involve both axonal degeneration and maladaptive synaptic plasticity. Understanding the molecular and cellular pathways that contribute to these processes has paved the way for novel therapeutic strategies aimed at preserving axonal integrity and modulating synaptic function. These approaches include targeting key mediators like SARM1, employing NMDA receptor antagonists to modulate synaptic plasticity, and using

TABLE 6. Role of BDNF in Synaptic Plasticity and Pain Modulation

Pathway Component	Role in Synaptic Modulation	Impact on Neuropathic Pain
BDNF	Promotes synaptic growth and plasticity	Released in response to nerve injury, enhances central sensitization through TrkB receptor activation
TrkB Receptors	Mediates BDNF signaling	Activation leads to downstream PI3K/Akt and MAPK pathways, increasing synaptic strength and LTP-like changes
NMDA Receptor Phosphorylation	Increases receptor activity	Enhances calcium signaling and contributes to persistent synaptic potentiation in pain pathways
AMPA Receptor Trafficking	Strengthens excitatory synapses	Increases synaptic response to glutamate, sustaining excitatory drive in pain-processing neurons

neuroprotective agents to stabilize mitochondrial function and reduce oxidative stress. Below, we discuss the potential of these therapies in detail.

A. MODULATING AXONAL INTEGRITY THROUGH SARM1 INHIBITORS

Given the critical role of SARM1 (Sterile Alpha and TIR Motif Containing 1) in mediating axonal degeneration, inhibitors of SARM1 activity have emerged as potential therapeutics to prevent axonal loss following nerve injury. SARM1 activation triggers a cascade that results in the depletion of NAD^+, a coenzyme essential for cellular metabolism and axonal maintenance. The loss of NAD^+ leads to energy failure within the axon, initiating processes that culminate in axonal disintegration. Therefore, SARM1 inhibitors aim to preserve NAD^+ levels within axons, thereby maintaining metabolic function and preventing the activation of the downstream pathways that lead to axonal breakdown.

Early preclinical studies have shown promise in using SARM1 inhibitors to maintain axonal integrity and reduce neuropathic pain symptoms. For example, genetically knocking out SARM1 in animal models of nerve injury has been shown to significantly delay Wallerian degeneration and protect against axonal loss. Similarly, small-molecule SARM1 inhibitors have demonstrated the ability to preserve NAD^+ levels in injured axons, reduce axonal degeneration, and alleviate pain-related behaviors in models of peripheral nerve injury. These findings suggest that SARM1 inhibition could be a viable strategy for preserving axonal structure and function in neuropathic conditions.

Despite the promise of SARM1 inhibitors, further research is needed to translate these findings into clinical therapies. Challenges include optimizing the delivery of these inhibitors to injured axons and ensuring their long-term safety and efficacy in human patients. Additionally, understanding the full spectrum of SARM1's role in neurodegeneration will be essential for developing effective therapeutic agents that minimize off-target effects.

B. TARGETING SYNAPTIC PLASTICITY WITH NMDA RECEPTOR ANTAGONISTS

Synaptic plasticity, particularly the process of long-term potentiation (LTP), plays a significant role in central sensitization, a key mechanism driving chronic neuropathic pain. NMDA (N-methyl-D-aspartate) receptors are crucial mediators of LTP, as their activation allows for calcium influx into postsynaptic neurons, which triggers a cascade of intracellular events that strengthen synaptic connections. This synaptic strengthening in the dorsal horn of the spinal cord and higher brain centers results in the amplification of pain signals. Therefore, NMDA receptor antagonists have been investigated for their potential to block this process and reduce pain.

Drugs such as ketamine, an NMDA receptor antagonist, have shown efficacy in reducing neuropathic pain by inhibiting calcium influx through NMDA receptors. By preventing the induction of LTP at synapses within the spinal cord and brain, ketamine can reduce the amplification of pain signals. Clinical studies have demonstrated that ketamine administration can provide short-term relief from neuropathic pain, particularly in cases that are resistant to conventional analgesics. However, the use of ketamine and other NMDA receptor antagonists in clinical settings is limited by their side effects, which include dissociative symptoms, hallucinations, and cognitive impairment.

The development of more selective NMDA receptor antagonists is therefore a critical area of research. Compounds that specifically target the NR2B subunit of the NMDA receptor, which is implicated in pain signaling but less involved in cognitive processes, have shown potential for providing pain relief with fewer side effects. These agents offer a promising approach for modulating synaptic plasticity in pain pathways while minimizing adverse effects.

C. NEUROPROTECTIVE AGENTS AND MITOCHONDRIAL STABILIZERS

Mitochondrial dysfunction plays a critical role in the pathophysiology of neuropathic pain, contributing to both axonal degeneration and synaptic dysfunction. The disruption of mitochondrial function leads to decreased ATP production, increased reactive oxygen species (ROS) generation, and impaired calcium buffering, all of which can exacerbate neuronal damage. Thus, agents that stabilize mitochondrial function hold potential for mitigating neuropathic pain by preserving energy metabolism and reducing oxidative stress.

Neuroprotective agents such as coenzyme Q10, a component of the electron transport chain, and mitochondrial-targeted antioxidants like MitoQ are being investigated for their ability to protect against oxidative damage in injured neurons. These compounds aim to reduce the burden of ROS

TABLE 7. SARM1 Inhibitors: Mechanisms and Therapeutic Potential

Inhibitor Type	Mechanism of Action	Potential Benefits in Neuropathic Pain
Genetic Knockout (SARM1 KO)	Prevents activation of SARM1 pathway	Delays Wallerian degeneration and preserves axonal integrity in animal models
Small-Molecule Inhibitors	Stabilize NAD^+ levels within axons	Maintain metabolic function, reduce axonal loss, and alleviate pain-related behaviors
NAD^+ Augmentation Strategies	Direct supplementation or boosting NAD^+ biosynthesis	Supports energy metabolism in injured axons, potentially preventing degeneration

TABLE 8. NMDA Receptor Antagonists and Their Role in Neuropathic Pain Management

Drug Type	Targeted Mechanism	Clinical Considerations
Ketamine	Non-selective NMDA receptor blockade	Effective in reducing pain but associated with side effects like hallucinations
NR2B-Selective Antagonists	Specifically inhibit NR2B subunit of NMDA receptors	Reduced cognitive side effects, promising for chronic pain management
Low-Dose NMDA Antagonists	Sub-anesthetic doses of NMDA inhibitors	Balances efficacy with reduced risk of side effects, suitable for chronic use

within mitochondria, thus preventing oxidative damage to lipids, proteins, and mitochondrial DNA. By maintaining mitochondrial integrity and function, these agents can potentially reduce axonal degeneration and support synaptic function, offering a dual benefit in the treatment of neuropathic pain.

In addition to antioxidants, compounds that enhance mitochondrial biogenesis and improve ATP production, such as nicotinamide riboside (a precursor to NAD^+), have shown potential in preclinical models of nerve injury. These agents can restore cellular energy balance and promote the survival of injured neurons, thereby reducing the impact of mitochondrial dysfunction on axonal and synaptic health.

The therapeutic efficacy of mitochondrial stabilizers has been demonstrated in various animal models, where they have been shown to reduce markers of neuronal damage and improve behavioral outcomes related to neuropathic pain. However, translating these findings into clinical practice requires a better understanding of the optimal dosing regimens and long-term effects of these compounds in human populations. Nevertheless, the focus on mitochondrial health represents a promising avenue for the development of neuroprotective strategies aimed at addressing both the structural and functional aspects of neuropathic pain.

By targeting both axonal degeneration and synaptic plasticity, these therapeutic approaches aim to address the multifaceted nature of neuropathic pain. The integration of SARM1 inhibitors, NMDA receptor antagonists, and mitochondrial stabilizers into therapeutic protocols holds the potential to provide more effective pain relief by preserving neuronal structure and function while minimizing the maladaptive changes that sustain chronic pain states.

V. CONCLUSION

Axonal degeneration and synaptic plasticity are fundamental processes contributing to the development and persistence of neuropathic pain. These processes interact intricately to disrupt normal neuronal function, leading to a chronic state of heightened pain sensitivity and altered pain processing. The molecular mechanisms underlying these changes include the activation of pathways such as SARM1, which drives axonal degeneration through NAD^+ depletion, as well as calcium dysregulation, which triggers proteolytic enzymes and mitochondrial dysfunction that further contribute to axonal breakdown. Additionally, synaptic plasticity mechanisms like long-term potentiation (LTP) are critical in maintaining the sensitized state of pain pathways. These changes are often perpetuated by neurotrophin signaling, particularly involving brain-derived neurotrophic factor (BDNF), which enhances synaptic strength and contributes to central sensitization.

Understanding these pathways provides a framework for developing targeted interventions aimed at preserving axonal integrity and modulating synaptic plasticity. This knowledge has led to the identification of several promising therapeutic strategies, including SARM1 inhibitors that aim to prevent axonal loss by maintaining NAD^+ levels, NMDA receptor antagonists that can reduce synaptic hyperexcitability, and mitochondrial stabilizers that address the metabolic disturbances underlying neuronal damage. These therapeutic approaches represent a multifaceted effort to interrupt the pathological processes driving neuropathic pain, offering potential for more effective treatment options.

However, despite the progress in understanding the molecular drivers of neuropathic pain, translating these findings into effective clinical treatments remains a significant challenge. The complexity of the interactions between axonal degeneration and synaptic plasticity, combined with the heterogeneity of neuropathic pain conditions, necessitates further research to refine these therapeutic targets and evaluate their long-term efficacy and safety in human populations. In particular, optimizing the delivery and specificity of these therapies will be crucial for minimizing side effects and maximizing therapeutic benefits.

Targeting the molecular drivers of axonal degeneration and maladaptive synaptic plasticity may offer new hope for alleviating chronic pain and enhancing the quality of life

for individuals suffering from neuropathic conditions. By continuing to advance our understanding of these underlying mechanisms, we can move closer to developing therapies that not only provide symptom relief but also address the root causes of neuropathic pain, potentially offering long-term solutions for patients. This approach emphasizes the need for a comprehensive, mechanism-based strategy in the treatment of neuropathic pain, one that acknowledges the complex interplay between peripheral and central nervous system changes and seeks to restore normal neural function. [1]–[24]

References

[1] L. Wright and S. Williams, "Advances in understanding glial cell function in cns disorders," in *Annual Conference of the European Society for Neuroscience*, Madrid, Spain, 2011, pp. 45–52.

[2] J. Clark and E. White, *Cellular Pathways in Neurodegeneration: Molecular Insights*, 1st. Berlin, Germany: Springer, 2011.

[3] O. Ford and I. Harris, "Inflammatory pathways in parkinson's disease: The role of microglia," *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, vol. 60, pp. 52–60, 2015.

[4] W. Chen, X. Wang, Q. Sun, *et al.*, "The upregulation of nlrp3 inflammasome in dorsal root ganglion by ten-eleven translocation methylcytosine dioxygenase 2 (tet2) contributed to diabetic neuropathic pain in mice," *Journal of Neuroinflammation*, vol. 19, no. 1, p. 302, 2022.

[5] S. Harrison and J. Davies, "Microglia activation in the pathogenesis of multiple sclerosis," *Frontiers in Neurology*, vol. 3, p. 43, 2012.

[6] P. Howard and A. Cooper, "Mechanisms of cellular stress in neurodegenerative diseases," *Cell Stress & Chaperones*, vol. 21, no. 5, pp. 709–720, 2016.

[7] Y. Ding, L. Hu, X. Wang, *et al.*, "The contribution of spinal dorsal horn astrocytes in neuropathic pain at the early stage of eae," *Neurobiology of Disease*, vol. 175, p. 105 914, 2022.

[8] D. Knight and M. Foster, *Cell Signaling in Neurological Disorders*, 2nd. New York, NY, USA: Wiley, 2014.

[9] K. Mason and J. Taylor, "Therapeutic approaches targeting synaptic dysfunction in autism," in *Proceedings of the International Conference on Neuroscience*, Paris, France, 2013, pp. 89–96.

[10] Q. Sun, T. Hu, Y. Zhang, *et al.*, "Irg1/itaconate increases il-10 release to alleviate mechanical and thermal hypersensitivity in mice after nerve injury," *Frontiers in Immunology*, vol. 13, p. 1 012 442, 2022.

[11] E. Murphy and H. Scott, "The role of mitochondrial dynamics in parkinson's disease," *Molecular Neurobiology*, vol. 49, no. 3, pp. 945–957, 2014.

[12] L. Peterson and B. Moore, "Neurovascular dysfunction in alzheimer's disease: A focus on blood-brain barrier integrity," *Journal of Cerebral Blood Flow & Metabolism*, vol. 37, no. 3, pp. 754–768, 2017.

[13] T. Russell and S. Gray, "Autophagy dysregulation in huntington's disease: Mechanisms and interventions," *Nature Neuroscience*, vol. 15, no. 10, pp. 1317–1325, 2012.

[14] T. Hu, Q. Sun, Y. Gou, *et al.*, "Salidroside alleviates chronic constriction injury-induced neuropathic pain and inhibits of txnip/nlrp3 pathway," *Neurochemical Research*, pp. 1–10, 2022.

[15] N. Thompson and W. Evans, "Glutamate signaling and excitotoxicity in neurodegeneration," *Neurobiology of Disease*, vol. 88, pp. 1–9, 2016.

[16] J. Liu, D. Shen, C. Wei, *et al.*, "Inhibition of the lrrc8a channel promotes microglia/macrophage phagocytosis and improves outcomes after intracerebral hemorrhagic stroke," *Iscience*, vol. 25, no. 12, 2022.

[17] A. Bell and R. Lewis, "The role of ion channels in epilepsy: Mechanisms and potential therapies," *Epilepsy Research*, vol. 116, pp. 95–107, 2015.

[18] R. Walker and T. Hughes, "Endoplasmic reticulum stress in neuronal injury and repair," *Journal of Cellular Neuroscience*, vol. 42, no. 1, pp. 57–68, 2010.

[19] W. Chen, T. Lan, Q. Sun, *et al.*, "Whole genomic dna methylation profiling of cpg sites in promoter regions of dorsal root ganglion in diabetic neuropathic pain mice," *Journal of Molecular Neuroscience*, vol. 71, no. 12, pp. 2558–2565, 2021.

[20] C. Watson and H. Mitchell, *Fundamentals of Neurodegenerative Diseases: A Molecular Perspective*, 1st. Boca Raton, FL, USA: CRC Press, 2012.

[21] R. Young and C. Morgan, "Calcium dysregulation in als: Pathophysiology and therapeutic approaches," *Neuroscience*, vol. 278, pp. 1–12, 2014.

[22] C. Zhang, M.-W. Hu, X.-W. Wang, *et al.*, "Scrna-sequencing reveals subtype-specific transcriptomic perturbations in drg neurons of pirtegfpf mice in neuropathic pain condition," *Elife*, vol. 11, e76063, 2022.

[23] E. Clarkson and G. Adams, "Protein misfolding and aggregation in amyotrophic lateral sclerosis," *Neurotherapeutics*, vol. 13, no. 3, pp. 624–632, 2016.

[24] E. Stewart and J. Lee, "Mechanisms of synaptic degeneration in alzheimer's and parkinson's diseases," *Journal of Molecular Neuroscience*, vol. 50, no. 2, pp. 193–204, 2013.